Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
7.68
-0.29 (-3.70%)
Aug 20, 2025, 4:00 PM - Market closed

Actuate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
10.866.483.273.82
Research & Development
13.4318.6821.7116.39
Operating Expenses
24.2925.1624.9720.21
Operating Income
-24.29-25.16-24.97-20.21
Interest Expense
-0.02-0.02-0.04-0.02
Interest & Investment Income
0.280.220.350.03
Other Non Operating Income (Expenses)
0.19-0.08-0.080.04
EBT Excluding Unusual Items
-23.83-25.04-24.74-20.16
Other Unusual Items
-0.85-2.25--
Pretax Income
-24.68-27.29-24.74-20.16
Net Income
-24.68-27.29-24.74-20.16
Net Income to Common
-24.68-27.29-24.74-20.16
Shares Outstanding (Basic)
17811
Shares Outstanding (Diluted)
17811
Shares Change (YoY)
1044.18%483.48%18.54%-
EPS (Basic)
-1.42-3.26-17.24-16.65
EPS (Diluted)
-1.42-3.26-17.24-16.65
EBIT
-24.29-25.16-24.97-20.21
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q